Cosmo Pharmaceuticals NV (XTER:C43)
€ 69 -0.5 (-0.72%) Market Cap: 1.10 Bil Enterprise Value: 966.46 Mil PE Ratio: 15.53 PB Ratio: 2.16 GF Score: 82/100

Full Year 2019 Cosmo Pharmaceuticals NV Earnings Call Transcript

Apr 03, 2020 / 08:30AM GMT
Release Date Price: €14.5
Operator

Ladies and gentlemen, welcome to the Cosmo Pharmaceuticals Full Year Results 2019 Conference Call. I am Alessandro, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to the management team of Cosmo Pharmaceuticals. You will now be joining to the conference room.

Alessandro E. Della ChÃ
Cosmo Pharmaceuticals N.V. - CEO & Executive Director

Good morning, everyone. I am Alessandro Della Chà . I'm the CEO of the company. Thanks for joining our conference call, and thanks for taking time in this difficult moment. The first thing that I would like to convey, the first message that it's important that reaches out everyone is that we are in good shape. Cosmo is in very good shape, I would say. Cosmo, as a pharmaceutical company, first of all, is exempt from business shutdown provisions in Italy. Therefore, we are continuing business as usual. The production is up and running. Our drugs

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot